Table 1.
Eligible studies' characteristics.
| # | Year | Antibody type | Dilution | Buffer | pH | T (°C) | Grading system∗ | SS sample | NSS sample | Entire sample |
|---|---|---|---|---|---|---|---|---|---|---|
| [16] | 2015 | Rabbit polyclonal | 1 : 200 | PBS | 7.2 | NR | 1 | 74 | 72 | 146 |
| [17] | 2016 | Mouse polyclonal | 1 : 150 | Citrate | 6 | 95 | 2 | 26 | 7 | 33 |
| [18] | 2013 | Rabbit polyclonal | 1 : 25 | EDTA | 9 | 95 | 1, 2, 4 | 50 | 85 | 135 |
| [19] | 2011 | Rabbit polyclonal | 1 : 400 | Citrate | 6 | 97 | 3 | 73 | 139 | 212 |
| [20] | 2016 | Rabbit polyclonal | 1 : 100 | EDTA | 6 | 95 | 2 | 62 | 322 | 384 |
| [21] | 2009 | Rabbit polyclonal | 1 : 20 | EDTA | 8.4 | ND | 2 | 35 | 73 | 108 |
| [22] | 2010 | Rabbit polyclonal | 1 : 100 | EDTA | 8.4 | 95 | 4 | 259 | 60 | 319 |
| [23] | 2009 | Rabbit polyclonal | 1 : 100 | EDTA | 8 | 97 | 1 | 20 | 143 | 163 |
| [24] | 2011 | Rabbit polyclonal | 1 : 20 | EDTA | 8 | 95 | 6 | 15 | 25 | 40 |
| [25] | 2012 | Rabbit polyclonal | 1 : 250 | EDTA | 8 | 97 | 1 | 42 | 69 | 111 |
| [26] | 2017 | Mouse monoclonal Rabbit polyclonal |
NR | Citrate | NR | 92 | 7 | 10 | 12 | 22 |
| [27] | 2007 | Rabbit polyclonal Rat monoclonal |
1 : 20 1 : 2 |
EDTA | 8 | 95 | 2 | 94 | 602 | 696 |
| [28] | 2013 | Rabbit polyclonal | 1 : 100 | EDTA | 6 | 95 | 5 | 5 | 37 | 42 |
Abbreviations: SS: synovial sarcoma; NSS: nonsynovial sarcoma; PBS: phosphate-buffered saline; EDTA: ethylenediaminetetraacetic acid; NR: not reported; ND: no details. ∗Grading system 1: 0 (<5% of cells positive); 1 (5–25% of cells positive); 2 (25–50% of cells positive); 3 (>50% of cells positive); Grading system 2: 0 (staining not visible); 1 (<26% of cells positive); 2 (26–50% of cells positive at 40x or >50% at 100x objectives); 3 (>50% of cells positive at 40x); Grading system 3: 0 (staining not visible); 1 (<5% of cells positive); 2 (6–25% of cells positive); 3 (26–50% of cells positive); 4 (51–75% of cells positive); 5 (>75% of cells positive); Grading system 4: 0 (no staining); 1 (<10% of cells positive); 2 (11–50% of cells positive); 3 (51–80% of cells positive); 4 (>80% of cells positive); Grading system 5: >20% of cells positive; Grading system 6: 0 (negative); 1 (weak); 2 (moderate); 3 (strong); Grading system 7: 0 (<5% of cells positive); 1 (5–25% of cells positive); 2 (25–50% of cells positive); 3 (50–75% of cells positive); 4 (75–90% of cells positive); 5 (>90% of cells positive).